MiR-21-5p-enriched exosomes from hiPSC-derived cardiomyocytes exhibit superior cardiac repair efficacy compared to hiPSC-derived exosomes in a murine MI model

Figure 2 Human-induced pluripotent stem cell-derived cardiomyocyte exosomes improve cardiac function in a murine myocardial infarction model. A and B: Electrocardiogram changes after left anterior descending following left anterior descending ligation; all rats displayed ST segment elevations (indicated by the white arrow); C: Bioluminescence imaging of induced pluripotent stem cells (iPSCs) and human-induced pluripotent SC-derived cardiomyocytes (hiPSC-CMs) on days 0, 3, and 7 post-cell transplantation; D: Left ventricular ejection fractions (LVEFs) were assessed on days 3, 7, 14, and 28 post-myocardial infarction (MI) injury and treatment. Data are shown as the mean ± SD from n = 7 biologically independent samples across different groups; E and F: LVEF (E) and LVFS (F) were measured on days 3, 7, 14, and 28 post-MI injury and treatment. Data are shown as the mean ± SD from n = 7 biologically independent samples across different groups. ^aP < 0.05, ^bP < 0.05. hiPSC-CM-exos: Human-induced pluripotent stem cell-derived cardiomyocyte-derived exosomes; iPSC-CMs: Induced pluripotent stem cell-derived cardiomyocytes; iPSC-exos: Induced pluripotent stem cell-derived exosomes; PBS: Phosphate-buffered saline.